Inovio Pharmaceuticals (INO) Current Leases (2019 - 2026)
Inovio Pharmaceuticals (INO) posted Current Leases of $2.9 million for Q1 2026, up 3.06% sequentially from $2.8 million in Q4 2025, and up 12.93% YoY from $2.6 million in Q1 2025.
Inovio Pharmaceuticals (INO) Current Leases (2019 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Current Leases for 8 years, with the latest figure at $2.9 million in Q1 2026.
- Quarterly Current Leases rose 12.93% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (up 12.93% YoY) and the FY2025 annual result came in at $2.8 million, up 13.02% from the prior year.
- Current Leases rose to $2.9 million in Q1 2026 per INO's latest filing, from $2.8 million in the prior quarter.
- Over five years, Current Leases peaked at $2.9 million in Q1 2026 and troughed at $2.1 million in Q3 2023.
- A 5-year average of $2.6 million and a median of $2.6 million in 2023 frame the typical range for Current Leases.
- The sharpest annual moves came in 2023 and 2025: Current Leases decreased 24.92% in 2023, then advanced 19.5% in 2025.
- Over 5 years, Current Leases stood at $2.8 million in 2022, then decreased by 14.17% to $2.4 million in 2023, then climbed by 3.77% to $2.5 million in 2024, then gained by 13.02% to $2.8 million in 2025, then climbed by 3.06% to $2.9 million in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $2.9 million, $2.8 million, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.92 Bn | 53.78 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 27.99 Bn | 9.60 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | - |
| 10 | Inovio Pharmaceuticals | 96.72 Mn | 96.72 Mn | - | 2.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.90 Mn |
| Mar 31, 2026 | 2.91 Mn |
| Dec 31, 2025 | 2.82 Mn |
| Sep 30, 2025 | 2.74 Mn |
| Jun 30, 2025 | 2.66 Mn |
| Mar 31, 2025 | 2.58 Mn |
| Dec 31, 2024 | 2.50 Mn |
| Sep 30, 2024 | 2.43 Mn |
| Jun 30, 2024 | 2.32 Mn |
| Mar 31, 2024 | 2.16 Mn |
| Dec 31, 2023 | 2.41 Mn |
| Sep 30, 2023 | 2.12 Mn |
| Jun 30, 2023 | 2.35 Mn |
| Mar 31, 2023 | 2.58 Mn |
| Dec 31, 2022 | 2.80 Mn |
| Sep 30, 2022 | 2.82 Mn |
| Jun 30, 2022 | 2.74 Mn |
| Mar 31, 2022 | 2.67 Mn |
| Dec 31, 2021 | 2.60 Mn |
| Sep 30, 2021 | 2.54 Mn |